Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Bruker (BRKR) Q2 Earnings Surpass Estimates, Margins Fall
by Zacks Equity Research
Bruker's (BRKR) second-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.
Henry Schein (HSIC) Q2 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Henry Schein (HSIC) sees dismal segmental performance in Q2 due to disruptions resulting from the coronavirus pandemic.
STERIS' (STE) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2021 results reflect strong performance by the Life Sciences segment despite the coronavirus-led economic crisis.
Pacific Biosciences (PACB) Posts Lower-Than-Expected Q2 Loss
by Zacks Equity Research
Pacific Biosciences (PACB) saw revenue decline in both its operating segments in Q2.
LabCorp (LH) Banks on Covance Amid Testing Volume Pressure
by Zacks Equity Research
LabCorp's (LH) COVID-19 related research too has been progressing well.
McKesson (MCK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2021 results benefit from strong U.S. Pharmaceutical and Specialty Solutions segment.
Hill-Rom's (HRC) Q3 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Hill-Rom (HRC) benefits from increased demand for critical care products due to the coronavirus outbreak.
Allscripts (MDRX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Allscripts (MDRX) witnessed decline in core Client Services and Software delivery unit revenues during Q2.
IDEXX (IDXX) Earnings Beat Estimates in Q2, Margins Rise
by Zacks Equity Research
IDEXX Laboratories (IDXX) registered strong contribution from its CAG business despite the pandemic-led challenges.
Teleflex (TFX) Beats Q2 Earnings Estimates, Margins Contract
by Zacks Equity Research
Teleflex (TFX) sales grow within the Americas attributable to Vascular Access and respiratory products, driven by COVID-19-led elevated demand.
DaVita (DVA) Earnings Beat Estimates in Q2, Revenues Miss
by Zacks Equity Research
DaVita's (DVA) dialysis services in the United States were solid in Q2.
Exact Sciences' (EXAS) Q2 Earnings Beat, Margin Declines
by Zacks Equity Research
Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q2 earnings.
NextGen Healthcare (NXGN) Tops Q1 Earnings & Revenue Estimates
by Zacks Equity Research
NextGen (NXGN) benefited from its Recurring segment in Q1.
Bio-Rad (BIO) Q2 Earnings Beat Estimates, Gross Margin Rises
by Zacks Equity Research
Bio-Rad's (BIO) second-quarter 2020 results reflect strong performance by the Life Sciences segment, boosted by coronavirus-led increased testing demand.
Tandem Diabetes (TNDM) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.
Integer Holdings (ITGR) Q2 Earnings Miss Estimates, Down Y/Y
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect from weak segmental performance and margin contraction.
Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) second-quarter earnings reflect weak segmental performance.
OPKO Health (OPK) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OPKO Health's (OPK) second-quarter results benefit from increase in RAYALDEE prescriptions.
Chemed (CHE) Q2 Earnings Beat Estimates, Margins Decline
by Zacks Equity Research
Chemed (CHE) witnesses solid revenue growth across key subsidiaries in Q2 earnings.
CONMED (CNMD) Q2 Loss Narrower Than Expected, Revenues Top
by Zacks Equity Research
CONMED's (CNMD) core units - General Surgery and Orthopedic Surgery - witnessed revenue decline in Q2.
Merit Medical (MMSI) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) reported a drop in revenues at every key operating segment in Q2.
Hologic (HOLX) Q3 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Hologic (HOLX) exhibited robust segmental growth in third-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Baxter (BAX) Earnings and Revenues Miss Estimates in Q2
by Zacks Equity Research
Baxter's (BAX) second-quarter earnings reflect weak performance across Medication Delivery, Pharmaceutical and Advanced Surgery business units and contraction in margins.
Cerner (CERN) Q2 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Cerner (CERN) second-quarter results benefit from gains in Subscriptions and Managed services units, and expansion in margins.